echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Heavy! Scientists have identified new targets that could help develop safe and effective CAR-T cell therapies for pancreatic cancer!

    Heavy! Scientists have identified new targets that could help develop safe and effective CAR-T cell therapies for pancreatic cancer!

    • Last Update: 2021-03-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    January 31, 2021 // -- A recent article published in the international magazine Clinical Cancer Research entitled "CEACAM7 Is An Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adeno" In the carcinoma study, scientists from institutions such as the University of London found a specific protein that could be used as a potential therapeutic target for the development of new treatments for pancreatic cancer, using the protein as a target to successfully develop a CAR-T cell therapy (a class of immunotherapy) to kill pancreatic cancer cells in preclinical models.
    CAR-T cell therapy is an immunotherapy that shows great hope in the treatment of certain blood cancers, but it is very difficult to use this therapy to treat solid tumors, one of the obstacles to the success of the therapy is that compared to cancer tissue, therapy can have a certain toxic effect on other tissues of the body, because most of the proteins currently targeted at CAR-T cells to treat pancreatic cancer and other solid tumors are present at low levels in other tissues, thus inducing toxic side effects.
    the study, researchers identified a protein called CEACAM7 that could be used as a safe therapeutic target to help develop new strategies for treating pancreatic catheterized adenocarcinoma (PDAC).
    photo source: Generated in the Solimena lab, Paul Langerhans Institute Dresden By using a special technique called immunostaining, the researchers analyzed the presence of CEACAM7 in human PDAC samples and normal tissues, and found that the PDAC samples tested A large portion of the samples were able to express CEACAM7 molecules, but the protein did not exist in some normal tissues, including tonsils, lung tissue, liver and prostate, suggesting that CEACAM7 may be an ideal target to help develop CAR-T cell therapy for pancreatic cancer.
    To determine the potential of CEACAM7 as a therapeutic target, the researchers developed a CAR-T cell that can target CEACAM7 molecules and apply it to PDAC cell line and PDAC preclinical models, where CAR-T cells can effectively target cells that act on the CEACAM7 molecule and eliminate cancer cells in late-stage PDAC preclinical models. 'The results of this study suggest that CEACAM7 can help us kill pancreatic cancer cells with CAR-T cells without any significant toxic effects on non-tumor tissue, which may allow us to see that this strategy can be used effectively in the future, and that other types of immunotherapy are also expected to target CEACAM7 molecules to treat pancreatic cancer,' said
    researcher John Marshall.
    So far, CEACAM7 is a relatively small protein studied, but it also appears to be a potential target for CAR-T cells that can treat pancreatic cancer, and it is clearly necessary to evaluate more antibodies against the molecule, not only to produce and detect larger CAR-T disks, but also to increase the resistance to the treatment of pancreatic cancer, and to rule out the presence of lower levels of CEACAM7 in normal tissues.
    CAR-T cells utilize immune cells (lethal T cells) from the patient's blood, which play a key role in the body's immune response; CAR, chimeric antigen receptors) to create CAR-T cells, CAR-T protein will enable CAR-T cells to identify specific proteins on the surface of cancer cells, CAR-T cells can also be in the laboratory proliferation and re-infusion back into the patient, and in the patient to identify and kill the surface of the cancer cells carrying targeted proteins. In the
    study, researchers created a new type of CAR using a structure of antibodies to the CEACAM7 protein, then modified the lethal T-cells so that they could show new CAR proteins on the surface to identify and bind CEACAM7, and were able to direct killer T-cells to kill cells that carried CEACAM7 only, which appeared to be just pancreatic cancer cells.
    Pancreatic catheter cancer is one of the most common pancreatic cancers, with the lowest survival rate of any common cancer, and only about 7% of those diagnosed with pancreatic cancer in the UK survive for five years or more;
    Macdonald, a British scientist working on pancreatic cancer, said: 'We are encouraged by the findings and give us some hope that in the future we can develop a new and innovative pancreatic cancer treatment.
    The study, in which researchers identified specific targeted proteins for pancreatic cancer for the first time, is now a step forward in the development of pancreatic cancer treatments by researchers who have studied the targeted protein and are likely to destroy pancreatic cancer cells in the future without damaging healthy tissue.
    Because treatment options are so limited and people affected by devastating diseases such as pancreatic cancer face a very low chance of survival, researchers expect more clinical trials of the protein in the future, and the findings may benefit more pancreatic cancer patients, just as we've seen new immunotherapy benefit more patients with other types of cancer.
    () References: Deepak Raj, Maria Nikolaidi, Irene Garces, et al. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma, Clinical Cancer Research (2021). DOI:10.1158/1078-0432.CCR-19-2163 【2】Researchers identify novel target that could improve the safety of CAR T cell therapy for pancreatic cancerby Queen Mary, University of London
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.